“We are delighted that clinical evidence supporting the ability of MAT2203 to safely and effectively improve outcomes for patients suffering from potentially deadly fungal infections will be presented ...
YONKERS, N.Y., April 27, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that the company ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
New data shows the Accelerate Arc System enables automated and rapid sample preparation that yields robust reportability and accurate microbial identification for positive blood cultures using MALDI ...
SAN FRANCISCO, April 1, 2019 /PRNewswire/ -- Geom Therapeutics, Inc., a privately held biopharmaceutical company focused on the development of novel antibiotics for multidrug-resistant (MDR) ...
Preanalytics – sample collection, processing, and other activities that make samples analyzable by diagnostics platforms – is one of the first steps of the intricate path to a correct diagnosis. Thus, ...
Cidara Therapeutics Highlights New Data from Multiple Rezafungin Studies Presented at ECCMID 2019 Data featured in three oral and five poster presentations reinforce potential of novel antifungal for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results